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Molecular targeting therapyThe genetic and epigenetic alterations occurring during the course of multistage colorectal carcinogenesis have
been extensively studied in the last few decades. One of the most notable ﬁndings is that the great majority of
colorectal cancers (N80%) have mutations in the adenomatous polyposis coli (APC) tumor suppressor gene.
Loss of functional APC protein results in activation of canonical Wnt/β-catanin signaling and initiates intestinal
carcinogenesis.Mutational inactivation of APC is theﬁrst genetic event, but colorectal cancer cells retain their de-
pendency on constitutive Wnt signal activation even after accumulation of other genetic events. Accordingly,
pharmacological blocking ofWnt signaling has been considered an attractive therapeutic approach for colorectal
cancer. Several therapeutics targeting various molecular components of the Wnt signaling pathway, including
porcupine, frizzled receptors and co-receptor, tankyrases, and cAMP response element binding protein
(CREB)-binding protein (CBP), have been developed, and some of those are currently being evaluated in early-
phase clinical trials. Traf2- and Nck-interacting protein kinase (TNIK) has been identiﬁed as a regulatory compo-
nent of the T-cell factor-4 and β-catenin transcriptional complex independently by two research groups. TNIK
regulates Wnt signaling in the most downstream part of the pathway, and its inhibition is expected to block
the signal even in colorectal cancer cells with APC gene mutation. Here we discuss some of the TNIK inhibitors
under preclinical development.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Colorectal cancer is a major cause of cancer death, accounting for
~700,000 deaths annually worldwide. The majority of colorectal cancer
patients without lymph node or distant organ metastasis can be readily
cured by surgical resection, with 5-year survival rates of N80% (Okuno,
2007; Watanabe et al., 2015), but the outcome of patients with distant
metastasis or postsurgical recurrence still remains unsatisfactory. Ad-
vances in combination chemotherapy [FOLFOX (folinic acid/ﬂuorouracil/
oxaliplatin), FOLFIRI (folinic acid/ﬂuorouracil/irinotecan), XELOX/
CAPOX (capecitabine/oxaliplatin), and their modiﬁcations] and sup-
portive use of therapeutic antibodies against vascular endothelial
growth factor (VEGF) (bevacizumab) and epidermal growth factor re-
ceptor (EGFR) (cetuximab and panitumumab) have signiﬁcantly
prolonged the survival of patients (Pasetto et al., 2005; Watanabe
et al., 2015), and themedian overall survival time of patients withmet-
astatic colorectal cancer has now exceeded 30 months in the most re-
cent phase 3 clinical trials (Cremolini et al., 2015). However, survival
prolongation does not necessarily mean that the disease has been
cured, and the 5-year survival rate of patients with stage-IV colorectal
cancer is still around 15% (Watanabe et al., 2015).
In a recent phase 3 clinical trial, regorafenib (BAY 73–4506) signiﬁ-
cantly prolonged the survival of patients withmetastatic colorectal can-
cer that had progressed after all approved standard therapies had failed
(Grothey et al., 2013). However, this survival prolongationwas still lim-
ited. The median overall survival period for patients treated with rego-
rafenib was 6.4 months, and that of controls was 5.0 months. Therapy-
related adverse events have been observed in 93% of patients receiving
regorafenib, which is a multikinase inhibitor whose precise molecular
target has not yet been established. It is therefore necessary to develop
new therapeutics that target the fundamental cause of colorectal carci-
nogenesis, and currently accumulated knowledge of colorectal cancer
genetics may provide some clues.
2. Wnt signaling and cancer
2.1. Frequent Wnt gene alterations in colorectal cancer
The greatmajority (N90%) of colorectal cancers carrymutations in at
least one Wnt signaling pathway gene, such as the adenomatousFig. 1. Normal intestinal epithelial stem cells reside in the bottom of the crypt intermingled wi
Constitutive activation ofWnt signaling byAPC orCTNNB1mutation transforms an intestinal epi
additional genetic alterations in the SMAD4, KRAS, and TP53 genes (right).polyposis coli (APC) and β-catenin (CTNNB1) genes. The APC gene was
initially identiﬁed as being causative for the familial adenomatous
polyposis (FAP) syndrome (Kinzler et al., 1991; Nishisho et al., 1991),
but later found to be frequently (N80%) mutated also in sporadic colo-
rectal cancers. APCmutations equally occur in replication error (RER)-
positive and -negative colorectal cancers (Huang et al., 1996; Homfray
et al., 1998) and are the earliest genetic event during the so-called ade-
noma–carcinoma sequence (Fig. 1) (Powell et al., 1992). CTNNB1muta-
tion is mutually exclusive to APC. About half of colorectal cancers with
wild-type APC have mutations in CTNNB1 (Morin et al., 1997). Recent
large-scale sequencing efforts by the Cancer Genome Atlas (TCGA)
and other projects have revealed genetic alterations in other Wnt sig-
naling molecules. Besides APC and CTNNB1, the genes encoding frizzled
10 (FZD10), T-cell factors-3 and -4 (TCF3/4) (TCF7L1/2), axis inhibitor 2
(AXIN2), and APC membrane recruitment protein 1 (AMER1, WTX, or
FAM123B) have been found to be mutated in colorectal cancers (Bass
et al., 2011; Cancer Genome Atlas, 2012).
2.2. Constitutive activation of Wnt signaling by genetic alterations
The APC protein forms a multiprotein complex with axin/axin2, ca-
sein kinase I α/ε (CKIα/ε), and glycogen synthase kinase 3β (GSK3β)
(Clevers & Nusse, 2012), which plays a central role in the degradation
of β-catenin and is thus referred to as the β-catenin destruction com-
plex. Cytoplasmic β-catenin is recruited into the complex, phosphory-
lated with CKIα/ε and GSK3β, and subsequently ubiquitinated with
β-TrCP-containing E3 ubiquitin ligase, which targets the β-catenin for
proteosomal degradation (Fig. 2A). Mutations of APC are observed in
the central part of the gene, called the mutation cluster region (MCR:
amino acid 1263–1587), resulting in a truncated APC protein (Miyoshi
et al., 1992) incapable of forming the destruction complex. Mutation
of the CTNNB1 gene has often been observed in the N-terminal phos-
phorylation sites at Ser45, Thr41, Ser37, and Ser33 (Polakis, 2000).
Either loss-of-function APCmutations or gain-of-function CTNNB1mu-
tations equally leads to inappropriate stabilization of β-catenin protein
and mimics the activation of Wnt signaling (Polakis, 2000).
Surplus β-catenin translocates to the nucleus, where it acts as a co-
activator for the T-cell factor (TCF)/lymphoid enhancer factor (LEF)
family transcription factors. TCF/LEF transcription factors transactivate
a large variety of target genes involved in the proliferation,th Paneth cells. Paneth cells constitute the stem cell niche through supply of Wnt3a (left).
thelial stemcell into adenoma. Adenoma develops into carcinoma throughaccumulation of
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Fig. 2. A Therapeutics for various molecular components of the Wnt signaling pathway. Abbreviations: APC, adenomatous polyposis coli; β-Cat, β-catanin; CBP, cAMP response element
binding protein (CREB)-bindingprotein; CK, casein kinase; Dvl, disheveled; GSK3β, glycogen synthase kinase 3β; LRP, low-density lipoprotein receptor-relatedprotein; TCF4, T-cell factor-
4, TNIK, TRAF2 and NCK-interacting protein kinase. B. In the majority of colorectal cancers, the β-catenin destruction complex is not properly formed due to truncation of APC.
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(JUN), c-myc (MYC), cyclin D1 (CCND1), multidrug resistance 1
(MDR1) (ABCB1), matrilysin (MMP7), axin2 (AXIN2), and survivin
(BIRC5) (Yamada et al., 2000). An updated list of the Wnt target genes
can be found on the Wnt Home Page posted by the Nasse Lab (http://
web.stanford.edu/group/nusselab/cgi-bin/wnt/).
Among the TCF/LEF transcription factor family consisting of LEF-1
(LEF1), TCF-1 (TCF7), TCF-3 (TCF7L1), and TCF-4 (TCF7L2), TCF-4 has
been implicated in colorectal carcinogenesis, as it is commonly
expressed in colorectal cancer cells. Mutant mice lacking Tcf7L2 show
complete absence of stem cell compartments and subsequent break-
down of the intestinal tissue (Korinek et al., 1998), indicating its crucial
role in the homeostasis of intestinal stem cells.
2.3. Colorectal cancer stem cells (CSCs) and Wnt signaling
The cancer stem cell (CSC) is a relatively new concept that has
emerged to explain how tumor heterogeneity originates from a smallproportion of undifferentiated cancer cells possessing self-renewal ca-
pacity and tumor propagation potential (Fabian et al., 2009). Normal in-
testinal epithelial stem cells reside in the bottom of the crypt
intermingled with Paneth cells, which constitute the stem cell niche
(Koo & Clevers, 2014) (Fig. 1). The stem cells give rise to transiently am-
plifying progenitor cells, which are subsequently committed to differen-
tiated epithelial cell lineages including enterocytes, goblet cells,
enteroendocrine cells, and Paneth cells (Vermeulen & Snippert, 2014).
Given the essential role of the Wnt signal for maintaining the adult
stem cells of various tissues/organs (Fodde & Brabletz, 2007), it is con-
ceivable that mutations constitutively activating theWnt signal subvert
the tightly regulated self-renewal program in intestinal epithelial stem
cells and generate CSCs. An active Wnt signaling pathway is closely as-
sociated with the CSC phenotype. Aldehyde dehydrogenase 1-A1
(ALDH1A1), CD133, CD44, Lgr5, CD26 (dipeptidyl peptidase IV:
DPPIV), CD24, CD166, EpCAM, andMusashi-1 have been reported as co-
lorectal CSCmarkers (Wielenga et al., 1999; O'Brien et al., 2007; Todaro
et al., 2010; Lin et al., 2011). Among them, CD44 and Lgr5/orphan G-
Table 1
Phase 1 ﬁrst-in-human studies of anti-Wnt therapeutics.
1. LGK974 (Wnt974)
Sponsor: Novartis Pharmaceuticals
Target molecule: Porcupine
Condition: Pancreatic adenocarcinoma
BRAF mutant colorectal cancer
Other tumor types with documented genetic alterations
upstream in the Wnt signaling pathway
2. Vanituctumab (OMP-18R5)
Sponsor: OncoMed Pharmaceuticals
Target molecule: Frizzled-1,−2,−5,−7,−8 receptors
Condition: Solid tumors
Adverse events: Grades 1/2: fatigue, vomiting, abdominal pain, constipation,
diarrhea, nausea.
Grade 3: diarrhea, vomiting
Publication: J Clin Oncol 31, 2013 (suppl; abstr 2540)
3. OMP-54 F28 (Decoy receptor)
Sponsor: OncoMed Pharmaceuticals
Target molecule: Frizzled-8 receptor
Condition: Solid tumors
Adverse events: Grades 1/2: dysgeusia, decreased appetite, fatigue, muscle
spasms, nausea, vomiting.
Bone fracture and increase of β-C-terminal telopeptide (β-CTX)
Publication: J Clin Oncol 32:5 s, 2014 (suppl; abstr 2505)
4. PRI-724 (CBP/catenin antagonist)
Sponsor: Prism Pharma
Target molecule: Interaction of β-catenin and CBP
Condition: Advanced solid tumors
Adverse events: Grades 2: diarrhea, bilirubin elevation, hypophosphatemia,
nausea, fatigue, anorexia, thrombocytopenia,
alkaline phosphatase elevation.
Grade 3: hyperbilirubinemia
Publication: J Clin Oncol 31, 2013 (suppl; abstr 2501)
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LEF (Wielenga et al., 1999; Yamamoto et al., 2003). A basic helix-loop-
helix transcription factor, achaete-scute like-2, is an important regulator
of stem cell fate (de Sousa et al., 2011), and its gene (ASCL2) is a target of
Wnt signaling (Jubb et al., 2006).
Due to the overexpression of ATP-binding cassette (ABC)-family
transporters functioning as drug-efﬂux pumps, CSCs often exhibit resis-
tance to conventional chemotherapeutic agents. Therefore, it is believed
that CSCs are responsible for cancer relapse after chemotherapy that
fails to eradicate the CSC reservoir. We have found that ABCB1 is one
of the target genes of TCF/LEF and demonstrated its functional involve-
ment in intestinal tumorigenesis (Yamada et al., 2000; Yamada et al.,
2003).
2.4. Aberrant Wnt signaling in other types of cancer
Oncogenic CTNNB1 mutations were ﬁrst found in colorectal cancer
and melanoma (Rubinfeld et al., 1997). Hepatocellular carcinoma
(HCC) is one of the most common tumors frequently harboring muta-
tions in the Wnt pathway genes, including CTNNB1 and AXIN1/2
(Satoh et al., 2000; Taniguchi et al., 2002). An aggressive form of
ﬁbromatosis known as desmoid tumor occurs at high incidence in FAP
patients carrying APC mutations (Tejpar et al., 2005). Mutations of
CTNNB1 have also been reported in sporadic desmoid tumors (Miyoshi
et al., 1998; Tejpar et al., 1999). Medulloblastoma, a pediatric brain
tumor of the cerebellum, harbors mutations in CTNNB1 and AXIN1
(Dahmen et al., 2001; Baeza et al., 2003). Loss-of-function mutations
of AMER1 occur in Wilms tumor, a pediatric kidney cancer (Major
et al., 2007; Rivera et al., 2007). A high frequency of oncogenic
CTNNB1 mutations (Cetta et al., 2000) and activating LRP5 mutations
have been discovered in thyroid tumors (Bjorklund et al., 2007). Various
Wnt pathway components are frequently over- and under-expressed in
different types of cancer through epigenetic or other molecular mecha-
nisms (Anastas &Moon, 2013). Together, these ﬁndings emphasize that
Wnt signaling could be a potential therapeutic target in various cancers.
However, potential crosstalk with other signaling pathways must be
carefully considered. In melanoma with BRAFV600E mutation, activation
ofWnt signaling has been reported to decrease tumor growth synergis-
tically with a BRAFV600E inhibitor, PLX4720 (Biechele et al., 2012), indi-
cating the potential tumor-suppressive activity of Wnt signaling.
3. Therapeutics targeting the Wnt signaling pathway
Based on the aforementioned genetic and biological data, it is evi-
dent thatWnt signaling is a major force driving colorectal carcinogene-
sis. Furthermore, colorectal cancer cells are highly dependent on
constitutively active Wnt signaling for cell survival, growth, and differ-
entiation.Morin et al. expressed the full-length APC cDNA in a colorectal
cancer cell line, HT29, using a zinc-inducible metallothionein promoter.
Restoration of the wild-type APC protein inhibited cell growth and in-
duced apoptosis (Morin et al., 1996), indicating the strong dependency
of colorectal cancer cells on constitutively activeWnt signaling. Accord-
ingly, various attempts have been made to develop therapeutics
targeting the Wnt pathway components (Fig. 2A), and some of these
are now under clinical evaluation. Such therapeutics is generally safe,
and no long-feared adverse effect of targeting intestinal epithelial
stem cells has been observed (Table 1).
3.1. Porcupine inhibitor
Palmitoylation is an essential step for the extracellular secretion of
Wnt proteins. Porcupine is a membrane-bound O-acyltransferase en-
zyme that catalyzes palmitoylation in the endoplasmic reticulum.
Chen et al. identiﬁed LGK974 (WNT974) through by screening a chem-
ical library of ~200 K compounds usingWnt3a-stimulatedmouse L-cells
stably harboring SuperTopFlash (Chen et al., 2009). LGK974 was laterfound to bind to and inhibit the porcupine enzyme. LGK974 suppresses
the growth of murine tumor xenografts established by mouse mamma-
ry tumor virus (MMTV)-driven ectopic Wnt1 expression. Crosstalk is
known to occur between Notch and Wnt signaling. LGK974 also exerts
anti-growth activity on head and neck squamous cell carcinoma cells
with loss-of-function mutations in the Notch signaling pathway (Liu
et al., 2013). A phase 1 open-label dose-escalation study of LGK974
sponsored by Novartis Pharmaceuticals is now ongoing.
3.2. Monoclonal antibody against frizzled receptors
Wntproteins exert their biological activities by binding to the seven-
pass transmembrane cell-surface G-protein-coupled FZD receptors.
There are 10 FZD receptors in the human genome. OMP-18R5
(vanituctumab) is a human monoclonal antibody that was originally
intended to target the FZD7 receptor but was later found to bind to
ﬁve FZD receptors (1, 2, 5, 7, and 8) at a conserved epitope across
their extracellular domains. OMP-18R5 binds to the FZD receptors and
inhibits their ligand binding and Wnt signaling (Gurney et al., 2012).
OMP-18R5 reduces the proliferation and tumor-initiating cell frequency
of pancreatic and breast cancer cells. Combination with gemcitabine
and paclitaxel further enhanced the anti-tumorigenicity activity. In the
majority of colorectal cancers, however, the β-catenin destruction com-
plex is not properly formed due to truncation of APC (Fig. 2B), and only
themolecules downstream of APC can be considered as targets for Wnt
signal blockage. Unfortunately, the FZD receptors transduceWnt signal-
ing upstream of APC. OMP-18R5 inhibited the growth of xenografted
human colorectal cancer with wild-type APC and CTNNB1, but not that
of colorectal cancer harboring APC or CTNNB1 gene mutations. Further-
more, OMP-18R5 was shown to inhibit the development of premalig-
nant pancreatic intraepithelial neoplasia (PanIN) in a transgenic
mouse model (Zhang et al., 2013). Phase 1 clinical trials of OMP-18R5
in combination with docetaxel, paclitaxel, and Nab-paclitaxel
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non-small cell lung cancer, breast cancer, and pancreatic cancer,
respectively.
3.3. Decoy receptor
OMP-54 F28 is a recombinant protein of the cysteine-rich domain of
FZD8 fused to the immunoglobulin Fc portion. OMP-54 F28 competes
with Fzd8 for binding to its ligand as a decoy receptor and antagonizes
Wnt signaling (Le et al., 2015). OMP-54 F28 inhibits tumor growth
and suppresses cancer stem cell function in a broad spectrum of
human malignancies. A phase 1 dose-escalation study of OMP-54 F28
monotherapy sponsored by OncoMed Pharmaceuticals has been con-
ducted in 25 patients with previously treated solid tumors. Dysgeusia,
decreased appetite, fatigue, muscle spasms, nausea, and vomiting of
grades 1 and 2 were observed in ≥20% of the patients. However, no
grade 3 or higher adverse event was reported. Phase 1b clinical trials
of OMP-54 F28 in combination with sorafenib, paclitaxel plus
carboplatin, and Nab-paclitaxel plus gemcitabine are being conducted
on patients with hepatocellular cancer, ovarian cancer, and pancreatic
cancer, respectively.
3.4. Low-density lipoprotein receptor-related protein 6 (LRP6)
LRP5 and LRP6 are single-pass transmembrane homologous proteins
that function as co-receptors for FZD. The binding of Wnt ligands in-
duces physical interaction of FZD with LRP5/6 and recruitment of
axins to the cell membrane. An anti-coccidial drug, salinomycin, was
recently found to target cancer stem cells. The anti-cancer stem cell
activity was mediated by inhibition of Wnt signaling through LRP6
degradation (Lu & Li, 2014). A few heavily treated patients with
therapy-resistant cancer reportedly received some clinical beneﬁts
from salinomycin monotherapy (Naujokat & Steinhart, 2012). Further-
more, an antihelminthic drug, niclosamide, a hepatoprotectant,
silibinin, and a natural plant polyphenol, rottlerin, have also been
shown to target LRP6 and inhibit Wnt signaling in various preclinical
models (Lu et al., 2011; Lu et al., 2012; Lu et al., 2014). Although rapid
clinical application of these well-characterized drugs might be expect-
ed, rigorous safety proﬁling and prospective clinical validation are still
mandatory. Furthermore, their speciﬁcity to Wnt inhibition has not
been sufﬁciently demonstrated. For example, salinomycin is known to
induce autophagy in colorectal cancer cells through the generation of
reactive oxygen species (Verdoodt et al., 2012).
3.5. Disheveled (Dvl)
Dvl binds directly to the intracellular domain of FZD membrane-
bound receptors and transduces Wnt signals from FZD to downstream
components. Small-molecule compounds NSC668036 (Shan et al.,
2005), FJ9 (Fujii et al., 2007), and 3289–8625 (Grandy et al., 2009) tar-
get the PDZ (PSD95/Disc large/Zonula occludens-1) domain of Dvl es-
sential for its interaction with FZD (Wong et al., 2003).
3.6. Casein kinase 1
The β-catenin degradation complex consists of glycogen synthase
kinase 3β (GSK3β), casein kinase 1α/ɛ (CK1α/ɛ), APC, and axins. β-
Catenin is phosphorylated sequentially by CK1α and GSK3β. The phos-
phorylated β-catenin is then subjected to rapid degradation by the
ubiquitin–proteasome pathway. An anti-pinworm drug, pyrvinium,
has been shown to selectively activate the CK1α kinase and inhibit
Wnt signaling (Saraswati et al., 2010; Thorne et al., 2010). The anti-
Wnt activities of two p38 mitogen-activated protein kinase (MAPK) in-
hibitors, TAK-715 and AMG-548, were found to be attributable to their
cross-reactivity with CK1δ/ɛ (Verkaar et al., 2011).3.7. Tankyrase inhibitors
XAV939, a small-molecule Wnt inhibitor, has been shown to molec-
ularly target tankyrases 1 and 2 (TNKS1/2) (Huang et al., 2009). These
tankyrases, poly-ADP ribosylate axins and poly-ADP ribosylated axins,
are subjected to ubiquitination and subsequent degradation. Inhibition
of poly-ADP ribosylation thus results in stabilization of axins and antag-
onized Wnt signaling. XAV939 effectively inhibited the proliferation of
APC-deﬁcient colorectal cancer cells, and thus TNKS has been consid-
ered a promising drug target. Recently, a selective TNKS inhibitor,
NVP-TNKS656, was identiﬁed through structure-based optimization of
XAV939 (Shultz et al., 2013). NVP-TNKS656 was orally administrable,
and its early clinical application is anticipated.
3.8. BBI608
A malignant tumor consists of heterogeneous cell populations, and
only a small proportion of cells actually have tumor-initiating activity.
These cancer stem cells (CSCs) can remain dormant for a long period
of time and thus are intrinsically resistant to conventional chemothera-
peutic agents that target rapidly dividing cells. BBI608 is a potent small-
molecule inhibitor of Stat3 (signal transducer and activator of
transcription-3) that targets cancer stem cells (Li et al., 2015). BBI608
has also been reported to inhibit β-catenin signaling, but the molecular
mechanism involved has not been explored. A recent international
phase 3 trial of BBI608 monotherapy against metastatic colorectal can-
cer, however, was prematurely terminated due to lack of expected efﬁ-
cacy in the interim analysis. BBI608 is currently under clinical
investigation in combination with other chemotherapeutic agents
such as paclitaxel, gemcitabine, sorafenib, temozolomide, pemetrexed,
and cisplatin.
3.9. ICG-001 and PRI-724
The histone acetyltransferase CREB-binding protein (CBP) and its
closely related homologue p300 both function as transcriptional
coactivators of the TCF4 and β-catenin complex (Li et al., 2007), but
the spectra of their transcribed genes are distinct. Enami et al. identiﬁed
ICG-001 by screening a library of 5000 secondary structure mimetics
(Emami et al., 2004). ICG-001 selectively antagonized the protein–pro-
tein interaction of β-catenin with CBP, but not with p300. Inhibition of
theβ-catenin/CBP interaction eliminated tumor-initiating cells and pro-
moted cell differentiation. The second-generation CBP/catenin antago-
nist, PRI-724, has been shown to have an acceptable safety proﬁle in a
phase 1 clinical trial and is now under further clinical investigation
(Lenz & Kahn, 2014). A phase 2 trial of combination chemotherapy in-
volving bevacizumab with and without PRI-724 is now being planned
for patients with newly diagnosed metastatic colorectal cancer.
4. TNIK as a regulator of Wnt signaling
TNIK was originally identiﬁed as the novel Germinal Center Kinase
(GCK) family, a subgroup of the STE20 kinase family, whose members
have been shown to interact with tumor necrosis factor (TNF)-recep-
tor-associated factor 2 (TRAF2) and NCK adaptor protein (NCK1) by
yeast two-hybrid screening (Fu et al., 1999). The TNIK gene is localized
in chromosome region 3q26, where gene ampliﬁcation often occurs in
various cancers (Brass et al., 1996; Sugita et al., 2000). TNIK mRNA is
expressed predominantly in heart and skeletal muscle and less abun-
dantly in the brain, kidney, and pancreas (Fu et al., 1999). Through a dif-
ferent approach, Taira et al. have also identiﬁed TNIK as a protein
interacting with Rap2, a Ras family small GTP-binding protein (Taira
et al., 2004). TNIK interacted with Rap2, but not with Rap1 or Ras.
TNIKdisrupted the actin cytoskeleton and thereby inhibited cell spread-
ing. TNIK was shown to be involved in the NF-κB and c-Jun N-terminal
kinase (JNK) pathways (Fu et al., 1999; Shkoda et al., 2012), but direct
Fig. 3. Co-crystal structure of PD407824 (white) with TNIK (green) (PDB code: 2X7F).
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the array of TNIK functions.
4.1. Identiﬁcation of TNIK as a regulator of Wnt signaling
Mahmoudi et al. have developed amethod to separate the prolifera-
tive crypt epithelium and differentiated villi epithelium fractions from
mouse intestine. Immunoprecipitation and mass spectrometry analysis
revealed that Tnik speciﬁcally interacted with Tcf4 in the crypt fraction,
but not in the differentiated villus fraction (Mahmoudi et al., 2009).
Consistently, immunohistochemical analysis revealed the nuclear local-
ization of Tnik inmouse and human intestinal crypt epithelial cells. Tnik
was detected in the Tcf4 transcriptional complex recruited to the pro-
moter region of the Wnt target gene, and this was essential for
transactivation of those genes, including Ccnd1 and Axin2. They con-
cluded that TNIK is essential for Wnt target gene expression.
We adopted a similar proteomic approach and independently veri-
ﬁed that TNIK was a component of the TCF4 and β-catenin transcrip-
tional complex in human colorectal cancer cells (Shitashige et al.,
2008). TNIK was essential for the transactivation of Wnt target genes
and the proliferation of colorectal cancer cells. Knockdown of TNIK
inhibited the growth of tumors produced by subcutaneous injection of
colorectal cancer cells into immunodeﬁcient mice (Shitashige et al.,
2010). These results indicate that TNIK is a feasible target for pharmaco-
logic intervention to ablate aberrant Wnt signaling in colorectal cancer.
4.2. TNIK is essential for axis formation
Mammalian TNIK consists of the N-terminal kinase domain and a
C-terminal GCK regulatory domain, whereas Xenopus TNIK lacks the
portion equivalent to the C-terminal half of human TNIK. We found
that Xenopus TNIK (XTNIK) was expressed maternally and that
knockdown of XTNIK by catalytically inactive XTNIK or antisense
morpholino oligonucleotides resulted in signiﬁcant malformations
with complete loss of the head and axis structures (Satow et al.,
2010). XTNIK enhanced, whereas knockdown of XTNIK inhibited, β-
catenin-induced axis duplication. XTNIK was recruited to the promot-
er region of Wnt target genes in a β-catenin-dependent manner
(Satow et al., 2010). All of these results indicate that the role of
TNIK in Wnt signaling is well conserved among species.
5. Synthetic small molecule inhibitors of TNIK
Because the great majority of colorectal cancers carry mutations in
either APC or CTNNB1, only Wnt signal molecules downstream of the
β-catenin destruction complex should be considered as therapeutic tar-
gets. TNIK is an essential regulator of the β-catenin and TCF4 transcrip-
tion complex, the most downstream component of Wnt signaling.
Knockdownof TNIKdemonstrated that TNIK is important forWnt signal
activation, and also clearly showed that colorectal cancer cells were
highly dependent on TNIK. TNIK phosphorylates TCF4, and this
phosphorylation is essential for the transcriptional activity of TCF4
(Shitashige et al., 2010). Therefore, a speciﬁc inhibitor of TNIK enzymes
would be an attractive drug targeting colorectal cancers associatedwith
aberrant activation ofWnt signaling due to such genetic alterations. Re-
cently, extensive efforts to identify such a novel TNIK inhibitor have
been reported.
5.1. Crystal structure of TNIK
The crystal structure of TNIKwith PD407824, aWee1Chk1 Inhibitor,
has been revealed (Fig. 3, PDB code: 2X7F). PD407824 (1, Fig. 4) was
originally discovered as an inhibitor of Chk1 and Wee1A kinases (with
IC50 values of 47 and 97 nM, respectively) (Squire et al., 2005; Palmer
et al., 2006), but the compound also inhibits TNIK with an IC50 value
of 0.7 nM (measured by the authors' group). PD407824 binds to theATP-binding site of TNIK by forming hydrogen bonds between the
succinimide moieties and the hinge region backbone amide NH of
Cys108 and the carbonyl O of Glu106. In addition, the phenolic hydroxyl
group forms another hydrogen bond with the main-chain carbonyl
group of Cys108. No detailed information about TNIK inhibition has
been disclosed.
5.2. CK2/TNIK dual inhibitor
Padgaonkar et al. have reported that their casein kinase 2 (CK2) in-
hibitor, ON 108600 (2, Fig. 4), is a dual inhibitor of CK2 and TNIK
(IC50 = 50, 5, and 5 nM for CK2α1, CK2α2, and TNIK, respectively)
(Padgaonkar et al., 2015). ON108600 showed excellent inhibitory activ-
ity against the triple negative breast cancer (TNBC) cell lines, BT-20, and
MDA-MB-231. Interestingly, ON 108600 exhibited signiﬁcant killing ac-
tivity against paclitaxel-resistant TNBC cell lines displaying a stem-like
phenotype. It is noteworthy that these paclitaxel-resistant TNBC cell
lines showedmarked upregulation of TNIK andWnt signaling. These re-
sults suggested that dual inhibition of CK2/TNIK kinasesmight be useful
for overcoming paclitaxel resistance in TNBC.
5.3. Aminothiazole-based TNIK inhibitors
Recently, the author's group has reported novel aminothiazole-
based TNIK inhibitors (Yamada et al., 2008). High-throughput screening
(HTS) of a small-molecule compound library against TNIK was carried
out, and NCB-0001 (3, Fig. 4) (IC50 = 9 nM, measured by mobility
shift assay (Kitagawa et al., 2012)) was identiﬁed as a potent TNIK in-
hibitor (Uno et al., 2013). Subsequent structural optimization led to
the discovery of N5355 (structure not disclosed), which is a potent
and selective TNIK inhibitor (IC50 of 3 nM). To investigate whether
N5355 inhibits Wnt signaling, a TCF/LEF reporter gene assay using a
Wnt3a ligand in HEK293 cells was performed. N5355 showed strong
Wnt signaling inhibitory activity with an IC50 value of 55 nM. In addi-
tion, treatment with N5355 resulted in markedly reduced expression
of Wnt target genes such as AXIN2 and MYC in the colorectal cancer
cell line HCT-116. The N5355 treatment also resulted in signiﬁcant re-
duction of protein expression for both axin2 and survivin. It was inter-
esting to note that N5355 killed only Wnt-dependent cancer cells but
had no effect on the viability of Wnt-independent cell lines.
Fig. 4. Structures of reported TNIK inhibitors.
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In contrast to our results, Ho et al. have reported that TNIK inhibitors
did not inhibitWnt signaling (Ho et al., 2013). They described a series of
phenylaminopyridine-based analogs with potent activity against TNIK,
as exempliﬁed by compound 4 (Fig. 4). Compound 4 is a strong TNIK in-
hibitor (IC50=8nM), but paradoxically hadweak potency againstWnt
signaling in a TCF4/β-catenin-responsive β-lactamase reporter gene
assay (IC50 = 6300 nM), being much higher than that expected from
its inhibitory activity in enzymatic assays. It was suggested that the “ki-
nase activity” of TNIKmaynot be important for activation ofWnt signal-
ing. The fact that TNIK knockdown dramatically decreased Wnt
signaling suggested that “TNIK protein” may play an important role
through scaffolding interactions.
These results suggest that aminothiazole-based TNIK inhibitors could
modulate Wnt signaling via conformational changes in TNIK, yielding
phenotypic effects different from those of phenylaminopyridine-based
TNIK inhibitors.
6. Pharmacological activities of TNIK inhibitors
TNIK is a multifunctional protein (Gui et al., 2011; Shkoda et al.,
2012), and its function is not limited to Wnt signaling. TNIK may affect
multiple different pathways and therefore have different effects in dif-
ferent disease sites. Through use of the aforementioned inhibitors,
TNIK has also been found to play roles in the AKT pathway, autophagy,
and epithelial–mesenchymal transition.
6.1. Autophagy
Recently, on the basis of a microarray-based comparative hybridiza-
tion assay of primary tumor samples, Yu et al. have found that the TNIK
gene was ampliﬁed in 7% of Chinese patients with gastric cancer (Yu
et al., 2014). In the PAMC82 human gastric cancer and T47D human
breast cancer cell lines, expression of both the TNIK gene and its protein
was found to be markedly increased in comparison with two other gas-
tric cancer cell lines, SNU638 and AZ521. NCB-0001 (3, Fig. 4) potently
inhibited the growth of the two TNIK-ampliﬁed cell lines PAMC82 and
T47D, but not that of the TNIK-nonampliﬁed cell line AZ521. Treatment
with NCB-0001 decreased the phosphorylation of AKT, as conﬁrmed by
siRNA-mediated TNIK knockdown experiments. In addition to AKT sup-
pression, NCB-0001 induced the expression of microtubule-associatedprotein 1 light chain (LC3), a marker of autophagy (Mizushima &
Yoshimori, 2007).
6.2. Epithelial–mesenchymal transition (EMT)
Recently, it has been reported that TNIK could be a therapeutic target
for the treatment of EMT-based disorders, such as cancer metastasis and
ﬁbrosis (Kim et al., 2014). Transforming growth factor (TGF)-β is the
major cytokine that triggers EMT by activating several pathways in-
cluding the Wnt/β-catenin signaling pathway (Fuxe et al., 2010;
Akhmetshina et al., 2012; Drabsch & ten Dijke, 2012). In human lung ad-
enocarcinoma A549 cells, nuclear translocation of TNIK protein was
strongly promoted by TGF-β1, resulting in a marked increase of TCF4-
mediated transcription. A small-molecule TNIK inhibitor, NCB-0005
(denoted KY-05009 in the paper) (5, Fig. 4), signiﬁcantly suppressed
the TGF-β1-induced activation ofWnt signaling and inhibited the nuclear
translocation of β-catenin in A549 cells. NCB-0005 was originally identi-
ﬁed by the authors' group (Yamada et al., 2008). In addition, treatment
with NCB-0005 resulted in marked reduction of EMTmarker expression,
including that of N-cadherin and vimentin. Moreover, NCB-0005 showed
strong inhibition of TGF-β1-inducedmigration and invasionof A549 cells.
7. Conclusion and future perspectives
The genetics of multistep colorectal carcinogenesis has been exten-
sively studied over the last few decades, and frequent alterations of
Wnt signaling genes in colorectal cancer were already recognized as
early as the 1990s. Canonical Wnt/β-catenin signaling regulates cell
fate determination, cell polarity, differentiation, and apoptosis, and it
is nowevident that activeWnt signaling is amajor force driving colorec-
tal carcinogenesis. Therefore, many attempts have been made to
pharmacologically block the pathway, and some small-molecule com-
pounds, a decoy receptor, and therapeutic antibodies targeting various
pathway molecules are now under evaluation in early clinical trials.
TNIK is an essential regulatory component of the TCF4 and β-catenin
transcription complex. The feasibility of targeting this kinase protein
has been proved by the discovery of several classes of small-molecule
inhibitors with strong anti-tumor activity.
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